Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs BIO-TECHNE Corp — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.33, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Roundhill NVDA WeeklyPay ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | TECH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $52.59 | $72.29 |
52-Week Low | $31.88 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW, the Roundhill NVDA WeeklyPay ETF, trades at $38.845, up 2.47% today, with a bullish technical signal from moving averages. It provides a synthetic leveraged position in Nvidia with a variable income stream, highlighted by frequent dividend distributions. Recent coverage from Seeking Alpha on July 9, 2026, notes its high trailing yield potential but fluctuating payouts, positioning it as a cash-generating hedge for Nvidia exposure.
The outlook hinges on Nvidia's performance, offering income opportunities through dividends but with volatility risks due to payout fluctuations. Key risks include dependency on Nvidia's stock and market sentiment shifts, requiring careful assessment for income-focused investors.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
